Lunchtime Industry Symposium

Our industry supporters are welcome to host sessions during the lunchtime breaks in the WAAVP 2021 programme. The sessions are available throughout the event ( one per day) and free to attend for all registered participants.

Monday 19th July

Symposium Title: 
Detection, Prevention, and Treatment:
Developing a Continuum of Care Program to Address Antiparasitic Needs of Cats


  • Evolution of Parasite Detection & Its Importance in Cats
    Dr. Yoko Nagamori, Zoetis
  • Key Components of Parasite Prevention for Cats
    Dr. Jessica Rodriguez ,Zoetis
  • Priorities for Treating Parasites in Cats
    Dr. Adriano Vatta, Louisiana State University, USA

Tuesday 20th July

Symposium Title:

NexGard Combo spot on for cats, a new antiparasitic drug to help controlling ecto and endoparasites of cats

Symposium Details:

The symposium will first come back on the importance of ecto and endo parasites in cats, sharing the results of epidemiological surveys conducted in Europe and in Asia. Then in a second part, the symposium will introduce NexGard Combo, a spot on formulation of esafoxolaner, eprinomectin and praziquantel. It has been approved by European Agnecy (EMA), the 13rd of January 2021. Esafoxolaner will be described: active S-enantiomer of afoxolaner. Then the different characteristics of NexGard Combo will be shared: PK of actives, safety studies, efficacy studies. The third part and conclusion will come back on the control of ecto-endoparasites of cats based on epidemiological conditions.


  • Introduction; Esafoxolaner; Conclusion on how to control parasitism in cats based on epidemiological conditions
    Frederic Beugnet, Boehringer Ingelheim Animal Health, FR
  • Latest epidemiological surveys on ecto & endoparasites in cats
    Domenico Otranto, Bari University, IT
  • NexGard combo PK, Safety & Efficacy data
    Eric Tielemans, Boehringer Ingelheim Animal Health, FR

Key Topics: Anti-parasitic drugs and drug development Parasites of companion animals

Wednesday 21st July

Symposium Title:
A newly developed broad-spectrum parasiticide treatment for dogs in an ever-changing landscape

Symposium Details:
Elanco’s acquisition of Bayer Animal Health positions Elanco as the world’s second largest provider of anti-parasitics. Elanco remains committed to ongoing investment in parasitology (including scientific studies presented at this WAAVP) and is now introducing Credelio Plus®, a novel oral endectocide for dogs. Active ingredients milbemycin oxime and lotilaner target larval and/or adult stages of various canine nematodes, and major tick and flea species, respectively.

Studies demonstrated Credelio Plus as highly effective (≥ 96.8%) against larval T. canis (L4) and A. caninum (immature adult L5). Efficacy against adult intestinal nematodes was confirmed by a multi-centre field study in veterinary practices in three European countries, proving to be highly efficacious (≥ 97.2%) in reducing the faecal egg count in dogs naturally infected with T. canis, A. caninum and T. vulpis.

The 100% prevention of heartworm disease is important considering many resistant isolates of D. immitis have been described from regions where this large multi-site field study was conducted. This study provided safety data in a long-term clinical setting with no dogs having treatment-related adverse reactions nor significant laboratory parameter alterations. In vitro genetic testing of 11 European isolates was conducted and compared to US isolates.

The three-month tick and flea field study demonstrated safety and efficacy against natural infestations by important species of ticks or fleas feeding on dogs, including the least susceptible arthropod R. sanguineus, and confirmed that dogs suffering from flea allergic dermatitis (FAD) may greatly benefit by administration of Credelio Plus.


  • The new Elanco, following the acquisition of Bayer Animal Health
    Patrick Meeus, Elanco, CH
  • Internal parasite impacts of a newly approved endectocide
    Brad Hayes, Elanco, UK
  • Heartworm field study and genetic analysis of EU and US heartworm isolates
    Lisa Young, Elanco, USA
  • Ecto-parasite impacts of a newly approved endectocide
    Sophie Forster, Elanco, UK

Key Topics: Parasites of companion animals; Anti-parasitic drugs and drug development; Arthropods; Helminths; Epidemiology

Thursday 22nd July

Symposium Title:
Symposium Details:

WAAVP2021, organisation and its affiliated groups on inclusion of an Industry symposium, are not endorsing any topics, content or opinions stated during these symposia.